Long-term survival rates with various chemotherapeutic regimens in Stages III and IV ovarian adenocarcinoma
- 1 June 1985
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 152 (3) , 310-314
- https://doi.org/10.1016/s0002-9378(85)80218-0
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Long-term survival after chemotherapy for advanced epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1984
- CISPLATIN-MECY (METHOTREXATE-LEUCOVORIN RESCUE PLUS CYCLOPHOSPHAMIDE) VERSUS CISPLATIN-CHAD (CYCLOPHOSPHAMIDE, HEXAMETHYLMELAMINE, DOXORUBICIN, AND CISPLATIN) AS INITIAL CHEMOTHERAPY IN STAGE III-IV OVARIAN ADENOCARCINOMA1984
- High-dose methotrexate with “rescue” plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence ofC parvum immunotherapyCancer, 1980
- Review of ovarian cancer at the University of Texas Systems Cancer Center, M. D. Anderson Hospital and Tumor InstituteAmerican Journal of Obstetrics and Gynecology, 1979
- SINGLE AGENT VS COMBINATION CHEMOTHERAPY IN TREATMENT OF OVARIAN CANCER1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958